| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1533-2500.2007.00157.X |
| P698 | PubMed publication ID | 17986159 |
| P2093 | author name string | Enno Freye | |
| Dagmar Braun | |||
| Joseph Victor Levy | |||
| P2860 | cites work | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment | Q33948133 | ||
| The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. | Q34581978 | ||
| Mechanisms of the placebo response and their impact on clinical trials and clinical practice | Q36055753 | ||
| Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study | Q39372438 | ||
| The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain | Q39436570 | ||
| Characterization of breakthrough pain by hospice patients and their caregivers | Q39444429 | ||
| Pain and its treatment in outpatients with metastatic cancer | Q39485856 | ||
| A validation study of the WHO method for cancer pain relief | Q39539028 | ||
| Peak plasma concentrations after oral morphine: a systematic review | Q43070517 | ||
| Influence of pH on the buccal absorption of morphine sulphate and its major metabolite, morphine-3-glucuronide | Q46379170 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| P433 | issue | 4 | |
| P921 | main subject | morphine | Q81225 |
| P304 | page(s) | 324-331 | |
| P577 | publication date | 2007-11-06 | |
| P1433 | published in | Pain Practice | Q2183039 |
| P1476 | title | Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet | |
| P478 | volume | 7 |
| Q39325643 | A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet |
| Q37215376 | Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research |
| Q39195016 | Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: Results of a descriptive cohort study. |
| Q37216421 | Characterizing episodic breathlessness in patients with advanced disease |
| Q58755045 | Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions |
| Q37154731 | Management of breakthrough pain in patients with cancer. |
| Q37974707 | Pharmacotherapy for breakthrough cancer pain |
| Q43085276 | Recent development in therapeutics for breakthrough pain |
Search more.